Skip to main content
Top
Published in: BMC Ophthalmology 1/2020

01-12-2020 | Multiple Myeloma | Case report

Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report

Authors: Emily A. Eton, Gary Abrams, Naheed W. Khan, Abigail T. Fahim

Published in: BMC Ophthalmology | Issue 1/2020

Login to get access

Abstract

Background

Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia and precursor to multiple myeloma. It has known ocular manifestations, but has not previously been shown to have an association with autoimmune retinopathy.

Case presentation

A 57 year-old female presented with 1 year of progressive, bilateral, peripheral vision loss, photopsias, and nyctalopia. Her fundus examination and extensive ancillary testing were concerning for hereditary versus autoimmune retinopathy. The patient was found to have anti-retinal antibodies against carbonic anhydrase II and enolase proteins with a negative genetic retinal dystrophy panel. Malignancy work-up was negative, but the patient was diagnosed with MGUS, a premalignant condition. The patient was treated with immunosuppressive therapies, with rituximab demonstrating the most robust therapeutic response with respect to patient symptoms and ophthalmic testing.

Conclusions

MGUS should be considered as a potential etiology of autoimmune retinopathy in patients without other autoimmune or malignant disease processes. Immunosuppressive therapy may be helpful in limiting disease progression, with rituximab showing efficacy in retinopathy refractory to other agents.
Literature
1.
go back to reference Agarwal A, Ghobrial I. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification and management of myeloma precursor disease. Clin Cancer Res. 2013;19(5):985–94.CrossRef Agarwal A, Ghobrial I. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification and management of myeloma precursor disease. Clin Cancer Res. 2013;19(5):985–94.CrossRef
2.
go back to reference Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–9.CrossRef Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–9.CrossRef
3.
go back to reference Saffra N, Rakhamimov A, Solomon WB, Scheers-Masters J. Monoclonal gammopathy of undetermined significance maculopathy. Can J Ophthalmol. 2013;48:e168–70.CrossRef Saffra N, Rakhamimov A, Solomon WB, Scheers-Masters J. Monoclonal gammopathy of undetermined significance maculopathy. Can J Ophthalmol. 2013;48:e168–70.CrossRef
4.
go back to reference Koo H, Oh DH, Chun YS, Kim JC. A case of crystalline keratopathy in monoclonal gammopathy of undetermined significance (MGUS). Korean J Ophthalmol. 2011;25(3):202–5.CrossRef Koo H, Oh DH, Chun YS, Kim JC. A case of crystalline keratopathy in monoclonal gammopathy of undetermined significance (MGUS). Korean J Ophthalmol. 2011;25(3):202–5.CrossRef
5.
go back to reference Tzelikis PF, Laibson PR, Ribeiro MP, Rapuano CJ, Hammersmith KM, Cohen EJ. Ocular copper deposition associated with monoclonal gammopathy of undetermined significance: case report. Arq Bras Oftalmol. 2005;68:539–41.CrossRef Tzelikis PF, Laibson PR, Ribeiro MP, Rapuano CJ, Hammersmith KM, Cohen EJ. Ocular copper deposition associated with monoclonal gammopathy of undetermined significance: case report. Arq Bras Oftalmol. 2005;68:539–41.CrossRef
6.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.CrossRef Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.CrossRef
7.
go back to reference Van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European myeloma network. Haematologica. 2014;99(6):984–96.CrossRef Van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European myeloma network. Haematologica. 2014;99(6):984–96.CrossRef
8.
go back to reference Grange L, Dalal M, Nussenblatt RB, Sen HN. Autoimmune retinopathy. Am J Ophthalmol. 2014;157:266–72.CrossRef Grange L, Dalal M, Nussenblatt RB, Sen HN. Autoimmune retinopathy. Am J Ophthalmol. 2014;157:266–72.CrossRef
9.
go back to reference Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30:127–34.CrossRef Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30:127–34.CrossRef
10.
go back to reference Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48:12–38.CrossRef Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48:12–38.CrossRef
11.
go back to reference Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol. 2013;58:430–58.CrossRef Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol. 2013;58:430–58.CrossRef
12.
go back to reference Liu Y, Magro C, Loewenstein JI, Makar RS, Stowell CP, Dzik WH, et al. A man with paraneoplastic retinopathy plus small fiber polyneuropathy associated with Waldenström macroglobulinemia (lymphoplasmacytic lymphoma): insights into mechanisms. Ocul Immunol Inflamm. 2015;23:405–9.CrossRef Liu Y, Magro C, Loewenstein JI, Makar RS, Stowell CP, Dzik WH, et al. A man with paraneoplastic retinopathy plus small fiber polyneuropathy associated with Waldenström macroglobulinemia (lymphoplasmacytic lymphoma): insights into mechanisms. Ocul Immunol Inflamm. 2015;23:405–9.CrossRef
13.
go back to reference Sen HN, Chan CC, Caruso RC, Fariss RN, Nussenblatt RB, Buggage RR. Waldenström’s macroglobulinemia–associated retinopathy. Ophthalmology. 2004;111:535–9.CrossRef Sen HN, Chan CC, Caruso RC, Fariss RN, Nussenblatt RB, Buggage RR. Waldenström’s macroglobulinemia–associated retinopathy. Ophthalmology. 2004;111:535–9.CrossRef
14.
go back to reference Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016;6:12–8.CrossRef Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016;6:12–8.CrossRef
15.
go back to reference Grewal DA, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review. Retina. 2014;34:827–45.CrossRef Grewal DA, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review. Retina. 2014;34:827–45.CrossRef
16.
go back to reference Ferreyra HA, Jayasundera T, Khan NW, He S, Lu Y, Heckenlively JR. Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol. 2009;127:390–7.CrossRef Ferreyra HA, Jayasundera T, Khan NW, He S, Lu Y, Heckenlively JR. Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol. 2009;127:390–7.CrossRef
17.
go back to reference DiLoreto DA, Williams Z, Khalifa YM. Autoimmune retinopathy treated with the fluocinolone acetonide intravitreal implant after intolerance to systemic immunosuppression. Invest Ophthalmol Vis Sci. 2014;55(13):2517. DiLoreto DA, Williams Z, Khalifa YM. Autoimmune retinopathy treated with the fluocinolone acetonide intravitreal implant after intolerance to systemic immunosuppression. Invest Ophthalmol Vis Sci. 2014;55(13):2517.
18.
go back to reference Davoudi S, Ebrahimiadib N, Yasa C, Sevgi DD, Roohipoor R, Papavasilieou E, et al. Outcomes in autoimmune retinopathy patients treated with rituximab. Am J Ophthalmol. 2017;180:124–32.CrossRef Davoudi S, Ebrahimiadib N, Yasa C, Sevgi DD, Roohipoor R, Papavasilieou E, et al. Outcomes in autoimmune retinopathy patients treated with rituximab. Am J Ophthalmol. 2017;180:124–32.CrossRef
19.
go back to reference Boudreault K, Justus S, Sengillo JD, Schuerch K, Lee W, Cabral T, et al. Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy. Orphanet J Rare Dis. 2017;12:129.CrossRef Boudreault K, Justus S, Sengillo JD, Schuerch K, Lee W, Cabral T, et al. Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy. Orphanet J Rare Dis. 2017;12:129.CrossRef
Metadata
Title
Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report
Authors
Emily A. Eton
Gary Abrams
Naheed W. Khan
Abigail T. Fahim
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2020
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-020-01423-y

Other articles of this Issue 1/2020

BMC Ophthalmology 1/2020 Go to the issue